期刊文献+

LC-ESI-MS/MS法快速测定人血浆中托莫西汀的浓度

Rapid determination of atomoxetine in plasma by LC-ESI-MS/MS
原文传递
导出
摘要 目的建立一种快速灵敏测定人体血浆中托莫西汀浓度的高效液相色谱串联质谱(LC-ESI-MS/MS)检测方法。方法以Agilent C_(18)反相柱(150 mm×2.1 mm,5μm)为色谱柱,流动相为乙腈(1%甲酸):0.02 mol·L^(-1)甲酸铵水溶液=80∶20(V/V);流速0.3 mL·min^(-1),柱温40℃。采用选择反应监测(SRM)对托莫西汀(m/z 256.1→44.1)和内标氟西汀(m/z 310.1→44.2)进行测定。结果托莫西汀的高(1 000μg·L^(-1))、中(500μg·L^(-1))、低(2μg·L^(-1))质量浓度标准血样的平均回收率分别为107.00%、103.51%和105.76%,日内(n=5)、日间(n=3)RSD均<15%;线性范围为1~1 500μg·L^(-1),回归方程为y=0.582 1ρ-2.581 4×10^(-4),r=0.997 5(n=5),分析方法的最低定量限为1μg·L^(-1)。结论该方法灵敏、准确、简单、快速,可用于托莫西汀临床血药浓度监测和药动学研究。 AIM To establish a rapid and sensitive LC-ESI-MS/MS method for atomoxetine assay in plasma. METHODS Atomoxetine was extracted with ethyl acetate-dichloromethane. The residues were analyzed with a LC-ESI- MS/MS system (Agilent Eclipse Plus Cls column, 150 mm × 2.1 mm,5μm) with the mobile phase consisted of acetonitrile( 1% formic acid) with 0.02 mol·L- 1 ammonium formate = 80: 20( V/ V), with a flow rate of 0.3 mL·min- 1 and temperature of 40℃. Selected reaction monitoring (SRM) using the precursor to product ion combinations of m/z 256.1→44.1 and m/z 310.1→44.2 was performed to detect atomoxetine and the internal standard, respectively. RESULTS The average recoveries for atomoxetine were 107.00%, 103.51% and 105.76%, respectively. The within-day ( n = 5) and between-day ( n = 3) precision of variation was less than 15%. The calibration curves for atomoxetine had good linearity within the range of 1 - 1 500μg- L- 1, r = 0. 997 5( n = 5). The limits of quantitation for palonosetmn was 1 μg·L-1. CONCLUSION The method provides a sensitive, accurate, precise and reliable analytical procedure for clinical monitoring of atomoxetine plasma and its phamaeokinefic studies.
出处 《中国临床药学杂志》 CAS 2010年第6期365-368,共4页 Chinese Journal of Clinical Pharmacy
基金 广东省自然科学研究基金资助(编号8151037001000001) 广东省医学科研基金立项(编号A2008559) 广东省医院药学研究基金资助(编号2010A08)
关键词 托莫西汀 血药浓度 高效液相色谱串联质谱检测法 atomoxetine plasma concentration LC-ESI-MS/MS
  • 相关文献

参考文献7

  • 1杜亚松.治疗ADHD的新药-托莫西汀[J].中国儿童保健杂志,2008,16(1):65-66. 被引量:14
  • 2魏斌,周伟,吴玉章.盐酸托莫西汀[J].中国新药杂志,2003,12(2):142-143. 被引量:19
  • 3魏宏伟.治疗注意缺陷障碍的新药——托莫西汀[J].国外医学(儿科学分册),2004,31(6):329-332. 被引量:10
  • 4Patel C, Patel M, Rani S, et al. A new high performance liquid chromatographic method for quantification of atomoxetine in human plasma and its application for phannacokinetic study[ J]. J Chromatog B,2007,850( 1 - 2) :356.
  • 5Guo W,Li WB, Guo GX, et al. Determination of atomoxetine in human plasma by a high performance liquid chromatographic method with ultraviolet detection using liquid-liquid extraction[ J]. J Chromatog B, 2007, 854( 1 - 2) : 128.
  • 6Mullan JH, Shugert RL, Ponsler GD, et al. Simultaneous quantification of atomoxetine as well as its primary oxidative and O-glucuronide metaborites in human plasma and urine using liquid chromatography tandem mass spectrometry (LC/MS/MS)[J] .J Pharm and Biomed Anal,2005, 38(4) :720.
  • 7Zhu HI, Wang JS, Donovan JL, et al. Sensitive quantification of atomoxetine in button plasma by HPLC with fluorescence detection using 4-(4,5-diphenyl-1H-imidazole-2-yl) benzoyl chloride derivafization[J]. J Chromatogr B,2007,846( 1 - 2) :351.

二级参考文献31

  • 1李雪荣.现代儿童精神病学[M].湖南:湖南科学技术出版社,1994.229.
  • 2Kratochvil CJ, Heligenstein JH, Dittmann R, et al. Atomoxetion and methylphenidate treatment in children with ADHD: a prospective,randomized, open-label trial [J]. J Am Child Adolesc Psychiatry, 2002, 41(7) :776-784.
  • 3Schachter HM, Pham B, King J, et al. How efficacious and safe is shortacting methylphenidate for the treatment of attention-deficit disorder inchildren and adolescents? A meta-analysis[J]. CMAJ, 2001, 165(11):1475-1488.
  • 4Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention-deficit/hyperactivity disorder [J].Heuropsychopharmacology, 20
  • 5Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study [J]. Pediatrics, 2001,108(5): E83-86.
  • 6Simpson D, Perry CI.Atomoxetion[J] .Paediatr Drugs,2003,5(6):407-417.
  • 7Wender PH, Wolf LE, Wasserstein J,et al. Adults with ADHD. An overview [J] .Ann N Y Acad Sci,2001,931(4): 1-16.
  • 8Wernicke JF,Kratochvil CJ.Safety profile of atomoxetine in the treatment of children and adolescents with ADHD[J]. J Clin Psychiatry, 2002,63 (Suppl 12) :50-55.
  • 9Wernicke J,Faries D,Girod D,et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults[J]. Drug Saf, 2003,26(10): 729-740.
  • 10Barr GL, Kroft J, Feng Y, et al. The norepinephrine transporter gene and attention-deficit hyperactivity disorder[J]. Am J Med Genet,2002,114(3):255-259.

共引文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部